Jefferies: Sichuan Kelun-Biotech-B (06990.HK) sac-TMT First-Line Lung Cancer Data Impressive; Maintains "Buy" Rating with Target Price of HK$520

Zhitong Finance APP has learned that Jefferies issued a research report maintaining a "Buy" rating and a target price of HK$520 for Kelun-Biotech-B (06990.HK). The bank noted that the company's data presented at ESMO 2026 on sac-TMT combined with pembro for first-line treatment of PD-L1-negative non-squamous non-small cell lung cancer showed impressive performance.